Derm-Biome Pharmaceuticals, Inc. reports positive preclinical data in melanoma and squamous cell carcinoma and initiates a program aimed at advancing topical skin cancer treatments to the clinic. The Canadian Business Journal

Vancouver, British Columbia, October 12, 2022 (Globe Newswire)-Derm-Biome Pharmaceuticals, Inc., a former clinical biopharmaceutical company based in Vancouver, which focuses on skin health and healthy aging , launched a program aimed at advancing topical treatments for precancerous skin disorders. To clinics such as actinic keratosis and non-melanoma skin cancers such as squamous cell carcinoma. Skin cancer accounts for one in three cancers diagnosed worldwide, making non-melanoma skin cancer the most common of all cancer types and a significant market opportunity. represents. According to a report by Grand View Research, Inc, the global actinic keratosis treatment market size alone is expected to reach $8.12 billion by 2028.

Current standard treatment for non -blackened skin cancer has surgical resection (costs and scars remains) and chemotherapy cream (long treatment period, severe side effects, and as a result treatment. The effect is limited. In pre-clinical trials using the first-generation culture of squamous cell carcinoma, the Derm-Bime compound is more significantly higher than the standard treatment 5-fluorowasil (5fu). To a large extent, it was completely selective in killing tumor cells, but was unable to kill normal cells. Derm-Biome has since developed a new generation of compounds, especially his drug, which has much higher cell poisoning and anti-inflammatory activity than his previous Derm-Bime drug candidates. I’m here.

Dr. Poul Sorensen, Derm-Biome CSO, said: Therapies for this disease, such as 5-fluorouracil, can cause severe side effects, making new non-toxic treatments an important unmet clinical need. Given the previous data that Derm-Biome compounds have potent anti-inflammatory activity, we are excited that our compounds may represent a mechanistically new class of compounds for treating malignant skin diseases. increase. “

Derm-Biome CEO Gordon Eberwein said: As people spend more leisure time in the sun, more elderly populations are susceptible to these tumors, and climate change will certainly increase the incidence of skin cancer. “

About DurmBiome Pharmaceuticals
Derm-Biome Pharmaceuticals, Inc. is a preclinical biopharmaceutical company with a suite of natural compound-based small molecules dedicated to improving skin health and healthy aging. Our compounds are well tolerated by the skin and exhibit novel anti-inflammatory, antimicrobial, antioxidant and antitumor properties.

https://derm-biomepharmaceuticals.com/

Source: Derm-Biome Pharmaceuticals, Inc

CBJ Newsmaker